Introduction {#s1}
============

Neuronal synapses are capable of regenerating SVs locally with high efficiency and fidelity in order to meet the demands of neuronal activity. The uniquely homogeneous sizes of SVs and their defined protein composition suggest the existence of a precise endocytic machinery that shapes and promotes the fission of SVs, either from the plasma membrane and/or endosome-like structures ([@bib44]; [@bib37]; [@bib41]; [@bib26]). Clathrin-mediated endocytosis is a classic example of vesicle formation mediated by a coat assembly, and it occurs at the synapse ([@bib37]; [@bib26]). It has been intensely studied for over four decades, yet numerous details, including when the endocytosed vesicle initiates acidification, remain unclear. The timing and regulation of vesicle acidification is an essential question, not only in the context of SV recycling and neurotransmitter uptake, but also for other endocytic pathways where lowering of the luminal pH is vital for a range of functions, such as separation of cargo from receptor (e.g. iron from transferrin; [@bib12]) or the activation of viral fusion proteins ([@bib47]).

Acidification of endocytic compartments is primarily mediated by vATPases. These proton pumps are large complexes composed of 14 different subunits that are organized into an ATP-hydrolytic domain (V~1~) and a proton-translocation domain (V~o~) ([@bib14]; [@bib19]; [@bib5]; [@bib21]). vATPases are particularly well studied at the synapse, where they traffic with other SV proteins through the SV cycle and generate a proton electrochemical gradient (∆µ~H+~) across the vesicular membrane, fueling the reloading of SVs with neurotransmitters. Yet, many details are not well understood: is vATPase fully active during the entire SV cycle, or is it regulated? If it is regulated, how and when is that done? While some have suggested that endocytic coated vesicles do not have acidic internal pH ([@bib2]; [@bib3]), other studies have shown that membrane-permeable, pH-sensitive, weak bases accumulate in the lumen of CCVs, indicating that acidification occurs in the presence of the coat ([@bib9]; [@bib46]; [@bib45]). To weigh in on this debate, and to investigate whether vATPase is active on CCVs, we have performed a full characterization of the ∆µ~H+~ at the single CCV level.

Results {#s2}
=======

We have prepared CCVs from mouse brain by adapting a published protocol ([@bib20]) ([Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Negative-stained electron microscopy (EM) images showed that the CCVs were abundant while almost no uncoated structures were present ([Figure 1B](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Immunoblotting for organellar marker proteins revealed high enrichment of synaptic vesicle proteins as well as clathrin and clathrin adaptors, whereas no significant presence of plasma membrane, endosome and proteasomal proteins was detected ([Figure 1C](#fig1){ref-type="fig"}). Detailed analysis of CCV samples by mass spectrometry revealed that the large majority of CCVs seems to be derived from the synapses, yet some CCV come from neuronal cell body/intracellular membranes (according to the AP2/AP1 ratio; [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Furthermore, cryo-EM classification of 43,711 individual particles revealed that the majority of vesicles had an intact clathrin coat ([Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}). The reconstruction from major classes of the imaged particles resulted in a highly symmetric structure ([Figure 1D](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2B--E](#fig1s2){ref-type="fig"})([Video 1](#video1){ref-type="video"}), which was comparable in size and symmetry to reconstructed 'barrel-like' empty clathrin cages ([Figure 1---figure supplement 2F](#fig1s2){ref-type="fig"}) ([@bib10]). The median size of CCVs (detailed in [Figure 1D](#fig1){ref-type="fig"} for the reconstructed CCV structure and in [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"} for the population of CCVs) is in line with previous measurements of CCVs from pig and bovine brains ([@bib34]; [@bib29]).

![Isolation of clathrin-coated vesicles from mouse brain.\
(**A**) Schema illustrating the isolation procedure of CCVs from mouse brains. Numbers 1 and 2 represent steps where Ficol and sucrose (at final conc. of 6.25 (wt/v)) were added to the sample, and where the sample was diluted 5x with buffer, respectively. See Suppl. Data for details. (**B**) Electron micrograph of isolated CCVs after negative staining. (**C**) Immunoblots of fractions collected during the CCV isolation protocol for various marker proteins (proteins were separated at the 4--15% gradient gel and detected by the Li-COR Odyssey imaging system). See also [Supplementary file 1](#supp1){ref-type="supplementary-material"} for mass spectrometry analysis of SVs and CCVs samples. (**D**) Reconstructed CCV from 6114 particles sized up to a diameter of 80 nm, with a D6 symmetry imposed, shows that ex vivo CCVs adopt the same 'barrel-like' structure as previously reported, and reveal the position of vesicle in its center (see also Suppl. Data and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). The median values extracted from the reconstruction of clathrin coat and vesicle within the coat are (note that the structure is a barrel): coated vesicle diameter 75 nm x 73.5 nm, coat thickness 15 nm, vesicle diameter 40 × 35 nm.](elife-32569-fig1){#fig1}

###### Reconstructed clathrin-coated vesicle from 6114 raw cryo-EM images of coated vesicle sized up to 80 nm, with D6 symmetry imposed.

10.7554/eLife.32569.005

The ∆µ~H+~ is composed of a chemical (∆pH) and an electrical gradient (∆ψ) which together provide the free energy required for loading the neurotransmitters in the vesicular lumen. Both ∆µ~H+~ components are important for the efficient import of different neurotransmitters, and can be regulated differently in various organelles ([@bib7]). To fully characterize the ∆µ~H+~ in CCVs, we performed measurements of ∆pH and ∆ψ at a single vesicle level, as described earlier ([@bib8]). ∆pH was measured in CCVs isolated from brains of mice expressing synaptopHluorin (spH, super-ecliptic pHluorin tagged to the luminal domain of VAMP2; [@bib17]) in the vesicular lumen (spH-CCVs), while ∆ψ was measured in CCVs isolated from the wild-type mouse brains after labeling with the potentiometric probe VF2.1.Cl ([@bib24]). The isolated CCVs were immobilized on glass coverslips, imaged under total internal reflection fluorescence (TIRF) illumination, and their fluorescence in response to ATP was measured ([Figure 2A--B](#fig2){ref-type="fig"}; [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The same measurements, as well as the basic characterization of vesicle acidification properties ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}), were performed with SVs isolated from the brains of transgenic mice (spH-SVs) and wild-type mice after labeling with VF2.1.Cl. Upon addition of ATP, only a minor fluorescence change was detected in CCVs when compared to the respective signals from the SVs ([Figure 2C--D](#fig2){ref-type="fig"}), indicating that the ATP-induced change in pH and membrane potential was much smaller in CCVs ([Figure 2E--F](#fig2){ref-type="fig"}). The distribution of fluorescence response of single CCVs and SVs clearly showed that the majority of the CCVs did not display any ATP-induced acidification ([Figure 2G--H](#fig2){ref-type="fig"}). The same results were obtained in the presence of chloride in the glycine buffer ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). The histogram of luminal pH of CCVs after ATP addition was fit to two Gaussian models revealing that a subpopulation composed of \~6% of the total CCVs acidified to the same mean extent as SVs ([Figure 2I--K](#fig2){ref-type="fig"}). Acidification of this small subpopulation is likely due to the presence of small SV contamination and/or damaged clathrin coats, as revealed by EM data ([Figure 2---figure supplement 4](#fig2s4){ref-type="fig"}). Altogether, our data provide evidence that a significantly smaller ∆µ~H+~ is formed across the vesicular membrane in the presence of a clathrin coat. This finding complements previous studies where delayed kinetics of spH quenching was observed during post-stimulus recovery at living synapses without synaptojanin-1, auxilin or endophilin-A that show delayed uncoating and prominently accumulate CCVs ([@bib18]; [@bib48]; [@bib25]).

![Measurement of the electrochemical gradient in SVs and CCVs.\
(**A--B**) Representative images of single (**A**) spH-CCVs and (**B**) VF2.1.Cl-labeled CCVs using TIRF microscopy. (**C--D**) Averaged fluorescence traces of single (**C**) spH-SV and spH-CCVs, and (**D**) VF2.1.Cl-labeled SVs and VF2.1.Cl-labeled CCVs over time in response to ATP. The control traces indicate the fluorescence response of the spH-CCVs or VF2.1.Cl-labeled CCVs over experimental timescale without ATP addition (the same traces were obtained for spH-SVs and VF2.1.Cl-labeled SVs). Error bars indicate SD from more than 1000 vesicles compiled from 4 to 7 experimental replicates. (**E**) Box plot representation of luminal pH of single SVs and CCVs after addition of 1 mM ATP (box: 1 st and 3rd quartile, line: median, whiskers: the minimum and maximum values). Note that the luminal pH of vesicles equilibrates to 7.4 as shown in [@bib8]. (**F**) Box plot representation of membrane potential of single SVs and CCVs after addition of 3 mM ATP. (**G--H**) Cumulative frequency plots generated from fluorescence change associated with ATP addition in (**G**) spH-SVs and spH-CCVs, and (**H**) VF2.1.Cl-labeled SVs and VF2.1.Cl-labeled CCVs. The dotted line indicates the fluorescence response of the probes over experimental timescale without ATP addition. (**I--J**) Histograms representing the luminal pH of (**I**) spH-SVs (n = 3,625) and (**J**) spH-CCVs (n = 2,233) upon addition of 1 mM ATP. Red lines indicate single and two-Gaussian models to SV and CCV populations, respectively. (**K**) The population of vesicles contributing to the lower pH (likely CCVs with damaged coat and/or very few SVs) in the CCV population consists of about 6% of the total vesicles measured.](elife-32569-fig2){#fig2}

The disruption of acidification in CCVs is likely not due to the absence of a vATPase complex on these vesicles ([@bib9]; [@bib42]). To verify this, we performed mass-spectrometry and immunoblotting for vATPase subunits in both CCV and SV samples ([Figure 3A](#fig3){ref-type="fig"}; [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}; [Supplementary file 1](#supp1){ref-type="supplementary-material"}). Indeed, both V~o~ and V~1~ complex subunits were present on CCVs as well as on SVs. However, due to the abundance of coat proteins in the CCV samples, we detected lower levels of vATPase subunits as well as other SV proteins in the CCV sample (total protein levels were equal in both samples; [Figure 3B](#fig3){ref-type="fig"}). The V~o~/V~1~ ratio was close to one in both samples, showing that a complete vATPase complex was present on SVs and CCVs ([Figure 3C](#fig3){ref-type="fig"}). Next, in order to test whether these vATPase complexes are active and able to hydrolyze ATP, we measured the ATPase activity in both CCVs and SVs ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), and observed that CCVs show significantly less ATPase activity compared to the same amount of SVs ([Figure 3D](#fig3){ref-type="fig"}). In addition, the ATPase activity in CCVs was not blocked by N-ethylmaleimide (NEM), an inhibitor of vATPase, showing that the remaining ATPase activity in CCVs was not due to the vATPase ([Figure 3E](#fig3){ref-type="fig"}). These data show that the lower ATPase activity measured in CCVs was likely due to impaired function of vATPases in CCVs. Taken together, vATPases are present on CCVs, but are not able to hydrolyze ATP and pump protons, resulting in inhibited ∆µ~H+~ generation.

![Functional analysis of the vATPase on CCVs.\
(**A**) Immunoblots of isolated SVs and CCVs for the clathrin light (LC) and heavy chains (HC), and SV marker proteins synaptophysin (Syph) and VAMP2 (left panel), as well as various V~o~ and V~1~ subunits of vATPase (right panel). (**B**) The ratio of the V~o~ and V~1~ as well as synaptophysin and VAMP2 (as SV markers) detected by immunoblotting in equal protein amount of CCVs and SVs (**C**) Normalized levels of V~o~ and V~1~ in CCV and SV samples, indicating that V~o~:V~1~ ratio is 1:1 in both preparations. (**D**) ATPase activity measured in 1.3 µg of isolated SVs and CCVs. (**E**) Blocking percentage of ATPase activity by NEM (vATPase inhibitor) in 1.3 µg of SVs and CCVs. Error bars in (**B--E**) represent SD of 3--4 experimental replicates (p\<0.01 for D and E, and \>0.05 for C).](elife-32569-fig3){#fig3}

The most plausible hypothesis to explain these results is that there are intact and functional vATPases on CCVs that are inhibited by the clathrin coat. In this scenario, vATPases should regain their function once the coat is removed. To test this hypothesis, we performed an in vitro uncoating by treating the CCVs with 300 mM Tris-buffer pH 9.0 (as in [@bib20]), followed by the measurements of ∆pH and ∆ψ in uncoated vesicles in the buffer with the neutral pH, as described above. Firstly, we checked for the uncoating efficiency after alkaline Tris-buffer treatment with negative-staining EM, and observed that almost all vesicles were uncoated ([Figure 4A](#fig4){ref-type="fig"}). The immunoblot analysis against clathrin heavy chain (HC) and light chain (LC) as well as adaptor proteins AP180 and AP2 on the uncoated vesicles and in the supernatant after uncoating has revealed that almost no clathrin HC,clathrin LC AP2 and AP180 proteins were detected on uncoated vesicles (all proteins were detected in the supernatant, [Figure 4B](#fig4){ref-type="fig"}), providing further evidence for a complete loss of clathrin lattice. When ∆pH and ∆ψ in uncoated vesicles was determined, we observed, intriguingly, that uncoated vesicles reached the same luminal pH and membrane potential as SVs upon application of ATP ([Figure 4C--D](#fig4){ref-type="fig"}). As a control, we performed the same alkaline Tris-buffer treatment with SVs, and observed no difference in the magnitude of ∆µ~H+~ in Tris-treated SVs, ruling out any perturbation caused by alkaline Tris-buffer to the vATPase function ([Figure 4C--D](#fig4){ref-type="fig"}). In addition to the uncoating of CCVs as detailed above, we have used other approaches to uncoat CCVs, namely by treating CCVs with 500 mM Tris pH 7.0, 5 mM DTT, 1 mM PMSF at 4°C for 4 hr ([@bib36]), or by adding purified auxilin, Hsp70 and Hsp110 proteins (to mimic physiological conditions) for 15 min at room temperature ([@bib39]). Both treatments have successfully uncoated all CCVs as verified by EM ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}), and we have detected full acidification of uncoated vesicles ([Figure 4E](#fig4){ref-type="fig"}). Taken together, these experiments demonstrate unequivocally that the vATPase activity is inhibited in the presence of a fully assembled clathrin coat. This inhibition is reversible and the vATPase regains its function once the coat is removed.

![CCV uncoating revealed that the vATPase is blocked by clathrin coat.\
(**A**) Electron micrographs of negatively stained CCVs before and after uncoating with 300 mM Tris-buffer pH 9.0. (**B**) Western blot of CCVs, uncoated vesicles and supernatant after uncoating shows dissociation of clathrin LC and HC, as well as AP180 and AP2, from the uncoated vesicle (proteins were separated at the 10% gel and detected by chemiluminescence). (**C--D**) Membrane potential (**C**) and luminal pH (**D**) of acidified SVs and CCVs before and after treatment with Tris-buffer (pH 9.0). Error bars represent SD of 3--4 experimental replicates done on over 1000 vesicles each. (**E**) Membrane potential of acidified CCVs after treatment with 300 mM Tris-buffer (pH 9.0), 500 mM Tris buffer (pH 7.0) and 'enzymatic' treatment with 1.7 µg auxilin, 4.8 µg Hsc70 and 1.7 µg Hsp110 proteins. Error bars represent SD of 3 experimental replicates done on over 1000 vesicles each. (**F--G**) Model of vATPase block by clathin coat: solved structures of vATPase, clathrin tripods and AP2 complex were used to check how vATPase fits within the clathrin lattice. The plasma membrane is depicted in light beige, clathrin triskelia in dark beige/brown; vATPase complex in gray (when inactive), light blue (when active) and dark green (V~1~H-subunit); AP2 complex in purple/blue/light green. As clathrin triskelia are recruited (through AP2), clathrin ring starts building around the vATPase complex. Insertion of the last triskelion of the clathrin ring would collide with the regulatory V~1~H-subunit of vATPase (**G**), thus we hypothesize that the displacement of regulatory V~1~H-subunit inwards results in the block of the vATPase activity. For more details, see Suppl. Data.](elife-32569-fig4){#fig4}

Discussion {#s3}
==========

Since, according to our knowledge, there is no evidence of a specific protein-protein interaction that blocks the vATPase activity at the newly formed vesicles at the synapse in the presence of clathrin or adaptor proteins, we propose that the vATPase may be sterically hindered by the three-dimensional clathrin scaffold that includes both clathrin triskelia and adaptor proteins (e.g. AP2, AP180, etc., adaptor proteins are essential to recruit clathrin triskelia to the membrane in order to initiate and organize the formation of clathrin coats). To see how the vATPase fits within the clathrin coat, we used the information provided by our structural analysis ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"} and Suppl. Data), as well as previously solved structures of the vATPase ([@bib50]; [@bib21]) and the clathrin coat ([@bib10]). Considering the size of vATPase and its V~1~ domain (\~25 nm and \~16 nm, respectively; [@bib31]; [@bib50], [@bib21]), we docked the solved structures of vATPase ([@bib50]) into a hexagonal ring of a clathrin coat (vATPase does not fit into a pentagonal ring)([Figure 4F--G](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}; [Videos 2](#video2){ref-type="video"}--[4](#video4){ref-type="video"}, for more information see Suppl. Data). Previously published studies, as well as our cryo-EM analysis of the clathrin coat, have revealed that upon complete hexagonal ring formation, the terminals of clathrin HCs are placed in a very close proximity (\<5 nm) to the vesicle membrane ([@bib4]). These terminal domains are suggested to form barrels with diameters \~ 10 nm at the inside surface of the cage (our data and [@bib10]). To fit in, the neck region of the vATPase (\~13 nm) where the regulatory V~1~H-subunit of the catalytic V~1~ domain is located would need to be constricted (for more information, see [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"} and Suppl data). Thus, we propose a hypothetical model where the steric hindrance provided by the formation of the clathrin coat around the vesicles blocks the vATPase activity ([Figure 4F](#fig4){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, [Videos 2](#video2){ref-type="video"}--[4](#video4){ref-type="video"}). Such a model is consistent with numerous publications (e.g., [@bib13]; [@bib33]; [@bib15]; [@bib6]; [@bib32]; [@bib31]; [@bib50]; [@bib43]; [@bib21]) and all our data, including the significantly reduced vATPase activity that we observed in isolated CCVs compared to SVs. It also allows for multiple layers of clathrin-coat formation regulation and provides a simple, yet elegant way by which the presence of a clathrin coat on the vesicle surface blocks the acidification process during its formation.

###### Animated 3D model of vATPase block by clathin coat (top view).

Note that all animations show the same process seen from different camera positions. Solved structures of vATPase, AP2 complex and clathrin tripods were used to see how vATPase fits within the clathrin lattice, thus all proteins have their 'true' dimensions. The plasma membrane is depicted in light beige, clathrin triskelia in dark beige/brown; vATPase complex in gray (when inactive), light blue/gray/dark green (when active; dark green = V~1~H-subunit), AP2 complex in purple/blue/light green. The plasma membrane starts as a flat surface on which the clathrin triskelia begin forming the ring formation around the vATPase (in clockwise direction). Only two AP2 complexes are depicted: upon cargo (yellow) binding, the AP2 complex alters its structure and recruits clathrin triskelia that start the formation of a clathrin ring around the vATPase. For the clathin ring to be 'closed', the 'last' triskelion to be inserted into the ring collides (gets in direct contact) with the vATPase, namely its regulatory V~1~H-subunit. We hypothesize that the regulatory V~1~H-subunit needs to be displaced inwards, resulting in the inhibition of the stalk rotation and thus block of the vATPase activity. So, upon insertion of the last triskelion in the clathrin ring, the vATPase becomes inactive (shown by a loss of color). The mechanical work of the clathrin coat proteins results in the membrane being pulled in, and as vesicle formation progresses, more clathrin triskelia are added. After vesicle is endocytosed, the clathrin coat disassembles (i.e. clathrin and adaptor proteins dissociate from the newly-formed vesicle), and the vATPase becomes active again. For more details, see Construction of the animated 3D model in the Supplementary Methods. A detailed (zoomed) view of regulatory V~1~H-subunit displacement is shown in [Video 4](#video4){ref-type="video"}.

10.7554/eLife.32569.017

###### Animated 3D model of vATPase block by clathin coat (side view).

Note that all animations show the same process seen from different camera positions). For details, see legend to [Video 2](#video2){ref-type="video"}.

10.7554/eLife.32569.018

###### Animated 3D model of vATPase block by clathin coat (front view).

Note that all animations show the same process seen from different camera positions. Here, detailed view of vATPase at the level of plasma membrane is shown (overview of the endocytic vesicle formation is shown in the [Videos 2](#video2){ref-type="video"} and [3](#video3){ref-type="video"}). Note that the time duration of the breaks between the vATPase rotation cycles has been shortened to better illustrate the vATPase activity. Upon binding cargo protein, the nearby AP2 complex alters its structure and recruits clathrin triskelia. Clathrin ring starts to be built around the vATPase complex (only terminal domain, linker, ankle and a part of distal segment can be seen in this view): the insertion of the last clathrin triskelion in the ring displaces the V~1~H-subunit of the vATPase. For more details, see Construction of the animated 3D model in the Supplementary Methods. After the vesicle is formed and endocytosed, the clathrin coat disassembles, and the vATPase subunits instantly resume 'original positions', bringing the vATPase in the active state again.

10.7554/eLife.32569.019

Our finding that clathrin coat-mediated vATPase inhibition prevents CCV acidification also resolves a longstanding debate in the field. It contributes to better understanding of the discrete steps of the SV cycle, now requiring clathrin uncoating upstream of acidification and neurotransmitter refilling. Interestingly, our model suggests that even partial formation of the clathrin coat around the vATPase may be sufficient to block its activity - such regulation may conserve ATP at the synapse. Finally, our finding that CCVs isolated from brain do not acidify matches findings in liver CCVs ([@bib11]), and may provide insight into other cellular processes that involve both clathrin and vATPases.

10.7554/eLife.32569.020

###### Antibodies used in this study.

  Antibody                          Characteristics         Producer
  --------------------------------- ----------------------- --------------------------
  ATP6V1A                           NBP1-33021 Polyclonal   Novus-Biologicals
  ATP6V1H                           Ab187706 Polyclonal     Abcam
  ATP6V1C1                          Ab87163 Polyclonal      Abcam
  ATP6V1E1                          Ab111733 Polyclonal     Abcam
  AP-2                              A2730 Monoclonal        Abcam
  AP-180                            155002 Polyclonal       Synaptic Systems (SySy)
  Clathrin-heavy chain (HC)         Ab2731 Monoclonal       Abcam
  Clathrin-light chain (LC)         Ab9884 Polyclonal       EMD-Millipore
  EEA1                              PA1-063A Polyclonal     ThermoFischer Scientific
  Na^+^/K^+^ ATPase                 Ab7671 Monoclonal       Abcam
  RPT4 (PMSF)                       Ab14715 Monoclonal      Abcam
  Proton ATPase (116 kDa subunit)   109003 Polyclonal       Synaptic Systems (SySy)
  Synaptotagmin-1                   105 011 Monoclonal      Synaptic Systems (SySy)
  Synaptophysin-1                   101 011 Monoclonal      Synaptic Systems (SySy)
  Synaptobrevin-2/VAMP-2            104 211 Monoclonal      Synaptic Systems (SySy)
  anti-mouse IgG (IR680)            P/N 925--68070          LI-COR
  anti-rabbit IgG (IR800)           P/N 926--32211          LI-COR
  anti-mouse IgG (H + L) HRP        62--6520                ThermoFischer Scientific
  anti-rabbit IgG (H + L) HRP       65--6120                ThermoFischer Scientific

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

spH21 ([@bib17]) mice were provided by Dr. V. N. Murthy (Harvard University, USA) and Dr. W. Tyler (Virginia Tech Carilion Research Institute, USA). Wild-type mice were obtained from the animal facility of Max-Planck Institute for Biophysical Chemistry (MPIbpc), Göttingen, Germany, or purchased from Janvier.

Isolation of synaptic vesicles and clathrin coated vesicles {#s4-2}
-----------------------------------------------------------

SVs were isolated from brains of mice as described by [@bib1] and [@bib8]. To isolate clathrin-coated vesicles (CCVs) from transgenic and wild-type mouse brains, we adapted a protocol from [@bib20]. Fifteen wild-type or transgenic mice (6--8 weeks postnatal) were decapitated and their brains were homogenized in ice-cold Buffer-A (MES 100 mM pH 6.5, EGTA 1 mM, MgCl~2~0.5 mM) supplemented with 200 µM PMSF (phenymethylsulfonyl fluoride) and 1 µg/ml pepstatin-A. The homogenate (H) was centrifuged (20,000 *g*, 20 min) and the resulting supernatant (S1) was further centrifuged at 55,000 *g* for 1 hr. The obtained pellet (P2) was re-suspended in Buffer A and diluted in Buffer A containing sucrose and Ficoll at final concentration of 6.25% wt/vol followed by centrifugation at 40,000 *g* for 40 min. The supernatant (S3) was then diluted 1:5 in Buffer A and subjected to ultracentrifugation (100,000 *g*, 1 hr). The obtained pellet (P4) contained coated vesicles, as confirmed by EM and immunoblotting. The pellet (P4) was next re-suspended in Buffer A and subjected to further centrifugation (20,000 *g*, 20 min). The obtained supernatant (S5) containing CCVs as well as other portion of SVs was overlaid on top of buffer A prepared with D~2~O containing 8% (wt/vol) sucrose and centrifuged at 25,600 rpm for 2 hr in a Beckman SW28 rotor. The final pellet containing pure clathrin-coated vesicles was resuspended in sucrose buffer (sucrose 320 mM, HEPES 10 mM, pH 6.5). Characterization of purifed SV and CCV samples was performed using western blotting and antibodies listed in [Table 1](#table1){ref-type="table"}, as well as mass spectrometry.

Immobilization of SVs and CCVs on glass coverslips {#s4-3}
--------------------------------------------------

Glass coverslips were cleaned by sonication in 2% Hellmanex-III solution (Hellma Analytics), and coated with 0.1% (wt/vol) poly-L-lysine (PLL) before use. 50--100 ng of SVs or 0.5--1 µg of CCVs were diluted in the assay buffer (glycine 300 mM, MOPS 10 mM, pH 7.4) and immobilized on the coverslips for 1 hr. The coverslips were then washed to remove the non-adsorbed vesicles and mounted in custom-made imaging chambers.

Measurement of ∆pH and ∆ψ in single SVs and CCVs {#s4-4}
------------------------------------------------

Single-vesicle imaging was performed as described previously ([@bib8]). We observed no difference between ratiometric values of spH in purified vesicles before and after addition of carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazon (FCCP) at pH 7.4, while acidifying the lumen by incubation of vesicles at pH 5.5 in the presence of FCCP significantly decreased the ratiometric value. This indicates that vesicles lose their luminal proton contents and reach equilibrium with their surrounding buffer during purification of vesicles and immobilization on glass coverslips. Acidification measurements were performed with vesicles isolated from the brain of transgenic mice (spH-vesicles). Potentiometric measurements were performed with the vesicles isolated from brains of wild-type animals after labeling with 100 nM of VF2.1.Cl. Acidification and potentiometric assays were performed in glycine buffer (300 mM glycine, 4 mM MgSO~4~, 10 mM MOPS, pH 7.4) which was free of membrane-permeable ions. Thus, it could be assumed that the contribution of ions other than protons to the acidification was negligible. Moreover, it can be assumed that these buffer conditions vATPase was the main protein responsible for the observed difference between SVs and CCVs. For both types of measurements, immobilized vesicles were imaged using a total internal reflection fluorescence (TIRF) microscope ([@bib8]). The samples were excited with the 488 nm line of an argon laser and the emission was collected through a 515/30 nm filter. Images were acquired using the Andor IQ2 software. The fluorescence changes induced after addition of the same concentration of Mg^2+^-ATP to SVs and CCVs were collected over time and corrected for bleaching of the fluorophore over the same experimental timescale before conversion to pH and membrane potential.

Image analysis {#s4-5}
--------------

The time series images were loaded as 3D stacks in MATLAB (Mathworks, Natrick, MA) and spot detection was performed using a previously described script ([@bib30]). A size cutoff (\<20 pixels), as well as an eccentricity cutoff (\<0.8 defining one as a line), were applied to the detected spots in order to remove aggregated particles from the analysis. The background for each vesicle was defined locally as the average intensity of neighboring pixels with the lowest intensity, and subtracted from the intensity of the spot in each frame. The fluorescence intensities were normalized to the integrated intensity of vesicles before the chemical perturbations. The normalized intensity, F~norm~(t) at time t, was then converted to pH and membrane potential using [Equation 1 and 2](#equ1 equ2){ref-type="disp-formula"}, respectively.$${pH_{(t)} = pK_{a} - log_{10}}\left\lbrack \frac{\left( {1 + 10^{pK_{a} - 7.4}} \right)\ F_{norm}(t)}{\ F_{norm}(t)} \right\rbrack$$where the pKa is equal 7.2 ([@bib8]).$$\Delta\Psi = k_{VF2.1.Cl}\ x\ \left( \frac{F\left( t \right) - F_{0}}{F_{0}} \right)$$where *k*~VF2.1Cl~ is equal 370.37 ([@bib8]).

Statistical analysis {#s4-6}
--------------------

For comparisons between SVs and CCVs a two-sided Student's t-test for unpaired samples was used (p values indicated in the respective figures), unless otherwise indicated.

Electron microscopy {#s4-7}
-------------------

Isolated SVs and CCVs were visualized by negative stain electron microscopy (EM). The main purpose of these experiments was to estimate the purity of the CCV sample (in addition to Western blotting and mass spectrometry), since the presence of contamination and uncoated SVs could interfere with the measurements. The EM detection of CCVs was also used to determine the size of CCVs, and the damage possibly inflicted on the coat by the purification procedure. Briefly, vesicles were applied to a formvar carbon-coated grid, washed with resuspension buffer, stained with 2% uranyl acetate for 1 min at room temperature, washed in distilled H~2~O and dried. Images were obtained at various magnifications by JEM 1011 electron microscope (80kV, JEOL, Germany), or by CM120 Philips electron microscope equipped with a TemCam 224A slow scan CCD camera (TVIPS, Gaunting, Germany). To measure the diameter of the CCVs, the obtained images were analyzed by Digital Micrograph 3.4 software (Gatan Inc.) ([@bib40]). The longest and shortest diameter of each vesicle was measured, and an average was calculated in order to determine the mean CCV diameter, which is then plotted as shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}.

To determine the ability of primary labeled anti-clathrin heavy chain (CHC) antibody X22 (Abcam) to detect the clathrin coat in its native-coat conformation, the purified CCV sample was subjected to immuno-gold labeling and inspected by EM. In short, the purified vesicles were added to coated carbon grids and fixing by 1% formaldehyde, followed by quenching with 20 mM glycine buffer and subsequent immunostaining with anti-clathrin HC antibody.

Uncoating of clathrin-coated vesicles {#s4-8}
-------------------------------------

To remove the clathrin coat from the CCVs, \~90 µg of isolated CCVs were diluted in 850 µl of pre-warmed uncoating buffer (Tris/Cl 300 mM, pH 9.0), and incubated at 37°C for 15 min, as described by [@bib20]. Alternatively, we also used another approach to uncoat \~30 µg CCVs by incubating them with 300 µl of 500 mM Tris/Cl, pH 7.0, 5 mM DTT, 1 mM PMSF at 4°C for 4 hr (these conditions, sometimes during the overnight incubation, are commonly used to extract coat proteins including clathrin, adaptor proteins, auxilin and Hsc70 from purified coated vesicles for further purification; [@bib36]). Lastly, auxilin, Hsc70 and Hsp110 proteins were expressed and purified as described previously ([@bib39]). Purified auxilin (1.7 µg), Hsc70 (4.8 µg) and Hsp110 (1.7 µg) proteins were added to 2 µg of isolated CCVs in the presence of 1.2 mM Mg^2+^-ATP in 100 mM MES pH 7.0, 20 mM imidazole, 25 mM KCl, 10 mM (NH~4~)2SO~4~, 2 mM Mg-acetate, 2 mM DTT (as in [@bib28]), for 15 min at room temperature.

For single-vesicle imaging of CCVs after uncoating, the vesicles were first immobilized on the PLL-coated coverslips as described above and were incubated in uncoating buffer for 15 min at 37°C before imaging. After uncoating, the coverslips were washed with the assay buffer and incubated in this buffer for 10 min to remove the residual Tris. In order to make sure that this treatment does not interfere with the v-ATPase activity, the same experiments were performed with SVs.

For electron microscopy, uncoated sample (irrespectively of how unocating is achieved) was centrifuged at 120,000 *g* for 15 min to separate the vesicles from the uncoated proteins. The resulting pellet was resuspended in sucrose buffer and used at appropriate dilution for EM.

For Western blot experiments, \~50 µg of isolated CCVs were diluted in 300 µl of pre-warmed uncoating buffer (Tris/Cl 300 mM, pH 9.0), and incubated at 37°C for 15 min. The sample was then centrifuged at 120,000 *g* for 15 min to separate the vesicles from the uncoated proteins. The supernatant was then removed and concentrated roughly 3x using centrifugal vacuum concentrator (Concentrator 5301, Eppendorf), while the resulting pellet was resuspended in 80 µl SDS-PAGE buffer. Isolated CCVs (diluted 1:10), uncoated vesicles and supernatant after uncoating were then analyzed by Western blot.

ATPase activity assay {#s4-9}
---------------------

The ATPase activity of 1.3 µg of isolated SVs and CCVs was measured in 96-well plate using the 'ATPase/GTPase Activity Assay Kit' (Sigma) according to the manufacturer's instruction. The acidification was performed by incubating the samples with 2 mM Mg^2+^-ATP in the assay buffer (300 mM glycine, 10 mM MOPS pH 7.4) for 15 min at room temperature. In this assay, the phosphate released by vATPase upon ATP hydrolysis is measured. To test for the free phosphate content in the SV and CCV samples, control samples with the same amount of isolated vesicles in the absence of ATP were measured. The absorbance of controls was then subtracted from the samples before calculating the amount of released phosphate.

For measuring the effect of N-ethylmaleimide (NEM) on the measured ATPase activity, the samples were incubated with 1 mM NEM for 10 min at room temperature before addition of Mg^2+^-ATP.

Cryo-electron microscopy and image processing {#s4-10}
---------------------------------------------

For sample preparation, 200 mesh Quantifoil R2/2 copper grids were glow-discharged and 0.65 mg/mL of the CCV preparation in 100 mM MES, 1 mM EGTA, 0.5 mM MgCl~2~ was added to the grid. The sample was plunge frozen with an FEI Vitrobot Mark V in liquid ethane.

The data were collected on a Talos Arctica (FEI) at 200 kV with a field emission gun and a nominal magnification of 45,000 at the Cryo-EM Swedish National Facility. The images were collected with a Falcon II and a dose rate of 9.53 e^-^ per Å^2^ per second. The recording time was 2.5 s, resulting in 30 frames and a total dose of 23.8 e^-^ per Å^2^. The frames were motion corrected and dose weighted with MotionCorr ([@bib16]) and the CTF was estimated with Gctf ([@bib49]). The pixel size for the images was 3.25 Å/pixel. For the processing, images with a box size of 130Åx130Å were manually extracted with RELION ([@bib38]). A total of 43,711 manually-picked individual particles from 2836 images were used for the 2D classification through RELION 2.0. After the classification, a new stack was formed for one vesicle based on the vesicle size. The image stack-classified into 16 classes with no (C1) symmetry imposed. The particles from the most populated well-defined 3D class were combined into a final stack. This stack was re-classified in three classes with D6 symmetry enforced. The particles of the most populated class were refined within RELION in D6. The gold standard FSC was calculated in RELION. Molecular graphics and analyses were performed with the UCSF Chimera package, a visualization system for exploratory research and analysis, developed by the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIGMS P41-GM103311) ([@bib35]). The structure has been deposited with the EMDB-ID \#4335.

Fitting vATPase structure into CCV structure and construction of the animated 3D model {#s4-11}
--------------------------------------------------------------------------------------

To see how the vATPase fits within the clathrin coat, we used the information provided by our structural analysis ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), as well as previously solved structure of the vATPase ([@bib50]; [@bib21]) and the clathrin coat ([@bib10]). Considering the size of vATPase and its V~1~ domain (\~25 nm and \~16 nm, respectively; [@bib31]; [@bib50], [@bib21]), we docked the solved structures of vATPase ([@bib50]) into a hexagonal ring of clathrin coat (vATPase does not fit into a pentagonal ring)([Figure 4E--F](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}; [Videos 2](#video2){ref-type="video"}--[4](#video4){ref-type="video"}, for more information see Suppl. Data). Previously published studies, as well as our cryo-EM analysis of the clathrin coat, have revealed that upon complete hexagonal ring formation, the terminals of clathrin HCs are placed in a very close proximity (\<5 nm) of the vesicle membrane ([@bib4]). These terminal domains are suggested to form barrels with diameters \~ 10 nm at the inside surface of the cage (our data and [@bib10]). To fit in, the neck region of the vATPase (\~13 nm) where the regulatory V~1~H-subunit of the catalytic V~1~ domain is located and protruded \~4 nm from the stalk would need to be constricted (based on [@bib50]; [@bib43]; [@bib21]). It is known that the V~1~H-subunit can inhibit the ATPase activity of eukaryotic vATPase when V~1~ is dissociated from V~o~ ([@bib33]; [@bib6]; [@bib15]). However, in holo (V~o~V~1~) vATPase the same subunit is required for the ATP hydrolysis ([@bib15]). Interestingly, recent biochemical and structural studies have revealed that the dual function of V~1~H-subunit is dependent on its position relative to the other V~1~ subunits ([@bib15]; [@bib31]), and might involve interactions with these subunits ([@bib15]). Further, the inhibitory effect of the V~1~H-subunit is thought to be a result of its rotation towards V~1~D ([@bib31]) and V~1~F ([@bib15]), which compose the central rotor of the complex ([@bib19]; [@bib50]; [@bib21]). Thus, we propose a model where the steric hindrance provided by the formation of the clathrin coat around the vesicles results in dislocation of the regulatory V~1~H-subunit towards the stalk ([Figure 4G](#fig4){ref-type="fig"}; [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, [Videos 2](#video2){ref-type="video"}--[4](#video4){ref-type="video"}). The displacement of the regulatory V~1~H-subunit respectively closer to the other V~1~ subunits, most probably V~1~D and V~o~d, and in turn would block the activity of the proton pump as suggested by several publications ([@bib6]; [@bib15]; [@bib32]; [@bib50]; [@bib43]; [@bib21]). Such a model is hypothetical but consistent with numerous publications ([@bib13]; [@bib33]; [@bib15]; [@bib6]; [@bib32]; [@bib31]; [@bib50]; [@bib43]; [@bib21]) and all our data, including the significantly reduced vATPase activity that we observed in isolated CCVs compared to SVs. It also allows for multiple layers of clathrin-coat formation regulation and provides a simple, yet elegant way by which the presence of a clathrin coat on the vesicle surface blocks the acidification process during its formation.

The animated 3D model of the vATPase block by clathrin coat was constructed using the original structures (as detailed below) and the custom-written plug-ins (<https://github.com/IraMilosevic/eLife-Farsi-Milosevic>; copy archived at <https://github.com/elifesciences-publications/eLife-Farsi-Milosevic>) ([@bib27]) for the 3D software Autodesk Maya (Autodesk Inc., San Rafael, CA). Information on protein structures was obtained from PDB based coordinates and the Uniprot database (PDB codes: 1XI4, 5TJ5: complete 3J9T, 3J9U, 3J9V, autoinhibited 5BW9). References used to model clathrin coat, AP2 and vATPase are listed in the Reference section. All proteins have their 'true' dimensions. The α- and β-linkers of AP2 are constructed to enable them to reach their maximal length. vATPase states are defined according to the \~120 °rotations: since autoinhibited V~1~ is crystalized in state 2, and autoinhibited V~o~ is crystalized in state 3, we chose state two to be the state where the stalk rotation is stopped when the clathrin N-terminus pushes it. We depict interplay of clathrin coat and vATPase in the context of a bare vesicle (40 nm in diameter): there are obviously many proteins on the vesicle, yet the proteins are likely mobile. Further, we detected all vATPase subunits on the CCVs, meaning that none of the subunit gets removed from the vATPase complex.

We referred to clathrin HC as 'HC'; V~o~ subunits were referred to using lowercase letters i.e. 'd', and V~1~ subunits were referred to using uppercase letters that is, 'D'; \'V~o~\'/\'V~1~\' lock refers to inactive vATPases; (structure) means that the protein/complex structure in this conformation is available. We considered five possible models:

(1)\'HC\' acts on \'d\'/\'D\'/\'F\' -\> \'V~o~\'/\'V~1~\' lock;

(2a) \'HC\' acts on \'H\' -\> \'H\' acts on \'D\' (structure), possibly deforming/pushing it (structure) -\> \'V~o~\'/\'V~1~\' lock;

(2b) \'HC\' acts on \'H\' -\> \'H\' acts on \'D\' (structure), possibly deforming/pushing it (structure) -\> \'V~1~\' lock, \'d\'/\'D\' interface disturbed -\> \'V~o~\' lock;

(3)\'HC\' acts on \'C\' -\> \'C\' acts on \'d\'/\'D\' -\> \'V~o~\'/\'V~1~\' lock;

(4)\'HC\' acts only on \'a\' -\> \'a\' acts on \'d\' -\> \'V~o~\'/\'V~1~\' lock;

(5)\'HC\' acts on unknown protein on the vesicle -\> \'V~o~\'/\'V~1~\' lock.

While all of these models may be possible, based on our data and the published literature we consider that the model (2) is the most likely way how clathrin coat inhibits vATPases. Specifically, clathrin HCs that have their N-termini located directly around vATPase will have at least one N-terminus at which the structures collide at the level of the regulatory V~1~H-subunit. Thus, V~1~H-subunit should be displaced in order for the clathrin hexagonal ring to reach its final position. Notably, the cytosolic part of the vATPase (structure 5BW9) adopts an autoinhibited structure that shows the V~1~H subunit affecting the V~1~D subunit. We hypothesize that the formation of clathrin lattice leads to a similar structure in which the proton pump rotation is blocked. Such a model is animated in 3D, and presented in [Videos 2](#video2){ref-type="video"}--[4](#video4){ref-type="video"}. Note that all movies show the same process seen from different camera positions (top view [Video 2](#video2){ref-type="video"}, side view [Video 3](#video3){ref-type="video"}, front view [Video 4](#video4){ref-type="video"}).
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###### Proteins identified from SV and CCV preparations by mass spectrometry.

20 µg protein from SV and CCV preparations were assayed by Q Exactive Mass Spectrometer (Thermo Scientific). MS/MS spectra were searched against an IPI mouse database (IPI, Mouse v3) with the ProteinPilot software (Applied Biosystems, USA). Common proteins from two trials are displayed. The identified vATPase (both V~o~ and V~1~) subunits are labelled in brown.
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Major datasets {#s7}
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The following dataset was generated:

Farsi ZGowrisankaran SKrunic MRammner BWoehler ALafer EMMim CJahn RMilosevic I2018Clathrin Coated Vesicle of 850 angstrom from mouse brain<http://www.ebi.ac.uk/pdbe/entry/emdb/EMD-4335>Publicly available at the Electron Microscopy Data Bank (accession no. EMD-4335)
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Decision letter
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Reviewing Editor
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United Kingdom

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Clathrin coat controls synaptic vesicle acidification by blocking vacuolar ATPase activity\" for consideration by *eLife*. Your article has been favorably evaluated by Randy Schekman (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This study investigates the role of the clathrin coat in regulating the vATPase activity of the underlying vesicle. The authors made use of a transgenic mouse expressing synaptopHluorin (spH), a chimeric construct consisting of VAMP2 followed by the pH-sensitive GFP derivative pHluorin. They then used well-established methods to prepare either clathrin-coated vesicle (CCV)-enriched fractions or synaptic vesicle (SV)-enriched fractions from the brains of both the transgenic mice and wild-type mice. The vesicles were immobilised onto coverslips, ATP was added, and TIRF microscopy was used to measure either the change in pH, using vesicles from the spH-expressing mice, or the change in membrane potential, using vesicles from the wt mice and a potentiometric probe. In both cases, the ATP-induced changes were much greater in the SVs than in the CCVs. However, they found that if they first uncoated the CCVs by treating them with a pH 9.0 buffer, the uncoated vesicles displayed the same ATP-dependent changes in lumenal pH and membrane potential as the SVs. These data strongly indicate that the coat inhibits the vesicle\'s vATPase activity.

The reviewers all found the work interesting, particularly the way the authors used the spH transgenic mouse to carry out studies on individual CCVs and SVs. However, they also all agreed that the model proposed by the authors is very speculative, that the assay used for uncoating the CCVs is far from physiological, and that some additional experiments are needed.

Essential revisions:

1\) The authors mention in their cover letter that they had tried uncoating the CCVs using similar conditions to those that are used in the cell, i.e. via auxilin and Hsc70, and didn\'t get full uncoating. However, it would be good to see the actual data. How incomplete was the uncoating? Did the authors see at least a partial increase in vesicle acidification? All three reviewers wanted to see data on vesicle uncoating under more physiological conditions, so it is likely that the readers will too.

2\) Another key experiment, suggested by one of the reviewers and supported by the others, is to add back coat components to the uncoated vesicles. This would both help to establish that the uncoating method they used is valid, and also allow the authors to look at the role of individual coat proteins (i.e., not only clathrin but also AP-2, AP180, etc.).

3\) The model needs to be toned down because there is really no experimental evidence to support it. If they can show, by carrying out the experiment suggested above, that it is clathrin and only clathrin that is inhibiting the vATPase, then their model has some support, but the method they used for uncoating clearly removes other proteins as well.

4\) There are some problems with the immunoblots.

4a) First, there is no information anywhere about what antibodies were used. This is essential information because there is so much variability in the quality of individual antibodies. Was the same anti-clathrin heavy chain antibody used throughout? In Figure 1C, lots of non-specific bands seem to be appearing, while in Supplementary Figure 8, it gives the sort of strong and specific signal one would expect, especially in purified CCVs.

4b) The dot blots (Figure 4B and Figure 1---figure supplement 1) are not acceptable. The dots are of varying sizes and appearances, and the method assumes that all of the antibodies are entirely monospecific, when clearly some of them are not. They need to be replaced by Western blots.

4c) There are some inconsistencies in the Western blots. In particular, in the blot in Figure 3A, where equal amounts of protein were loaded into the SV and CCV lanes, there is a stronger signal for VAMP2 and other SV proteins in the SV lane than in the CCV lane, which is understandable because much of the protein in the CCV lane is clathrin and other coat proteins. Similarly, in Supplementary Figure 8, there is a stronger signal for VAMP2 in the SV lane. However, there is also a stronger signal for α-adaptin (AP-2) in the SV lane, which doesn\'t make sense. Moreover, the iBAQ values, which are reasonably quantitative within a single sample, clearly indicate that this is not the case. If one normalizes the iBAQ data to assume that there is twice as much VAMP2 in the SVs as in the CCVs (which is the sort of difference suggested by the Western blot), then there should be about four times as much α-adaptin in the CCVs as in the SVs, not less α-adaptin in the CCVs.

5\) The authors say: \"Clathrin-mediated endocytosis is a classic example of vesicle formation mediated by a coat assembly, and it is the prominent endocytic pathway at the synapse.\" This sentence should be toned down as CME is not necessarily the sole endocytosis pathway for synaptic vesicle endocytosis (Watanabe et al. 2013; Kononenko et al. 2014). Moreover, it is very relevant to this study to know where clathrin is used. If it is on the plasma membrane, then acidification will take place in the CCV or, as proposed here, after uncoating. However, if clathrin is required on endosome-like vesicles (Watanabe et al., 2014) then acidification could occur before clathrin coated bud formation, making the issue of acidification less relevant.

6\) The difference in CCVs vs. SVs is revealed by assays performed in a buffer composed of 300 mM glycine, 4 mM MgSO4, 10 mM MOPS, pH 7.4, devoid of \"membrane permeable ions\". How is the pH equilibrated to 7.4? In this buffer, SVs can acidify only to pH 7.0, far from the physiological pH. In the \"full characterization\" of SVs, Figure 2---figure supplement 2, by adding 30 mM chloride SVs can acidify to pH 5.5, the physiological pH. Why did the authors use the buffer without membrane permeable ions? They should repeat the measures with chloride to assess whether CCVs are able to acidify or not in this more physiological context.

7\) Is there any evidence that acidification is delayed at synaptic terminals? Available data on acidification, based on spH measurements in cultured neurons, seems to be at odds with a significant delay (Atluri and Ryan 2006; Leitz and Kavalali 2011; Soykan et al., 2017). This should be discussed. Moreover, there are mutant mice (synaptojanin KO, endophilin TKO) for which CCV uncoating seems to be delayed. Is there any indication that acidification is delayed in these mice?

10.7554/eLife.32569.029

Author response

> Essential revisions:
>
> 1\) The authors mention in their cover letter that they had tried uncoating the CCVs using similar conditions to those that are used in the cell, i.e. via auxilin and Hsc70, and didn\'t get full uncoating. However, it would be good to see the actual data. How incomplete was the uncoating? Did the authors see at least a partial increase in vesicle acidification? All three reviewers wanted to see data on vesicle uncoating under more physiological conditions, so it is likely that the readers will too.

This point has been well taken, and we have now carried out uncoating experiments using two additional and independent procedures. In the previous version, we used 300mM Tris-buffer pH 9 for 15 min to uncoat CCVs, as described by Maycox et al. JCB 1992. We have now also uncoated CCVs while maintaining neutral pH by treating them with the buffer containing 500mM Tris, pH 7.0, 5 mM DTT, 1 mM PMSF at 4C for 4 hours ° -- these conditions are commonly used to extract coat proteins including clathrin, adaptor proteins and/or auxilin from purified coated vesicles for further purification (e.g., Prasad and Keen, Biochemistry 1991). Full uncoating of CCVs and recovery of full acidification was observed (see new Figure 4 in the revised manuscript).

Second, as requested by the reviewers, we have carried out uncoating experiments using purified auxilin, Hsc70 and Hsp110 proteins (through collaboration with Prof Eileen Lafer, San Antonio, TX, USA). We were pleased to observe that the addition of highly purified auxilin, Hsc70 and Hsp110 for 15 min at room temperature has uncoated all CCVs efficiently, and revealed that uncoated vesicles acidify (see new Figure 4).

In sum, as presented in new Figure 4, uncoating enhances acidification of the CCV sample to the level of SV sample regardless of whether uncoating was achieved enzymatically, or by treatment with "non-physiological" uncoating buffers.

> 2\) Another key experiment, suggested by one of the reviewers and supported by the others, is to add back coat components to the uncoated vesicles. This would both help to establish that the uncoating method they used is valid, and also allow the authors to look at the role of individual coat proteins (i.e., not only clathrin but also AP-2, AP180, etc.).

We agree that such an experiment would be highly attractive, however, while the formation of empty clathrin cages in vitro (without vesicle) is well established for over a decade, we are not aware of any reports showing that uncoated vesicles can be re-coated in vitro by adding coat components.

Nevertheless, we have tried several conditions to recoat recently uncoated vesicles. In one of the approaches, we first uncoated freshly prepared CCVs using the aforementioned 300 mM Tris-buffer approach, and then added recombinant clathrin HC and LC obtained from Prof Lafer. While we have detected partial recoating (clathin coats were detected on \~9% of vesicles by EM, no coated vesicles were detected in uncoated samples) and a shift towards lower membrane potential values was observed when averaging the whole vesicle population, the recoating was not very efficient under these conditions. These data are now included below as additional data for reviewers. We spent several months trying to address this point, but apparently this is far from trivial as suggested by the lack of published evidence showing that such recoating can be achieved in vitro.

Additional data for reviewers:

Recoating of uncoated clathrin-coated vesicles

To remove the clathrin coat from the CCVs, \~20 µg of isolated CCVs were diluted in 300 µl of pre-warmed uncoating buffer (Tris/Cl 300 mM, pH 9.0), and incubated at 37 °C for 15 min. The sample was then transferred to dialysis cassette (Slide-A-Lyser 2K, Thermo Scientific) and dialysed overnight at 4°C against MES 100 mM pH 7.0, imidazole 20 mM, KCl 25 mM, (NH~4)2~SO~4~ 10 mM, Mg-acetate 2mM, DTT 2mM. Additional 1h was allowed at room temperature before the sample was carefully taken out of the dialysis cassette. The vesicles were immobilized on the PLL-coated coverslips and labeled with VF2.1.Cl as detailed above. Alternatively, for the EM experiments, the sample taken out of the dialysis cassette was centrifuged at the table-top centrifuge at maximal speed for 20 minutes, and 3-5 µl taken from the bottom of the tube were put to the formvar carbon coated 100-mesh grids. The samples are the stained with 2% uranyl acetate for 1 min at RT, dipped in distilled H~2~O, dried and subsequently inspected by JEM 1011 microscope (80kV, JEOL, Germany).

![Partial recoating of previously uncoated CCVs was not robust enough to produce a significant difference in acidification assay.\
(**A**) Electron micrographs of negatively stained sample after the vernight "recoating" treatment as detailed in Materials and methods. While coat formation sometimes occurs without the vesicle at its center, several vesicles surrounded by a new coat are clearly seen (indicated by a white arrow). Scale bar 200 nm. (**B**) Membrane potential of acidified vesicles after the overnight "recoating" treatment Error bars represent SD of 3 experimental replicates.](elife-32569-resp-fig1){#respfig1}

![Cryo-electron tomography on partially uncoated CCVs reveals that clathrin coat-vATPase interactions exist.\
(**A**) Electron micrographs of partially uncoated CCVs (in tightly packed CCVs, vATPase could not be detected). (**B**) Zoomed image of two vesicles at different views, as indicated. Red arrowhead points presumably to vATPase, blue arrowheads to clathrin filaments. See cryo-electron tomography Video for a better view.](elife-32569-resp-fig2){#respfig2}

> 3\) The model needs to be toned down because there is really no experimental evidence to support it. If they can show, by carrying out the experiment suggested above, that it is clathrin and only clathrin that is inhibiting the vATPase, then their model has some support, but the method they used for uncoating clearly removes other proteins as well.

There might be a misunderstanding here. Our title, Abstract and manuscript text state clearly that it is the complete clathrin coat that controls synaptic vesicle acidification, and not clathrin itself. The proposed model is based on the contribution of adaptor proteins since adaptor proteins (e.g. AP2, AP180) are essential for recruiting clathin triskelia to the membrane in order to initiate and organize the formation of clathrin coat around the vesicle. It is not possible to form clathrin coats around vesicles without adaptor proteins. vATPase is the largest protein complex on synaptic vesicles that is, due to its size, most likely positioned in one of the hexagon rings of the clathrin coat. Given that we find the whole vATPase complex on CCVs (Figure 3 and the proteomics data), and that the structure of vATPase and clathrin coat are known, we have examined, by using the original structures in their real dimensions, how clathrin coat can accommodate the large vATPase complex. While we are not yet able to detect vATPase at CCVs in the cryo-EM experiments, we have succeeded in generating a reconstruction of most abundant CCV moiety (Figure 1---figure supplement 2 and Figure 1D), and we have docked the published vATPase structure into this reconstruction (Figure 3---figure supplement 2). The collision between vATPase structure and our reconstructed CCV (identical to the clathrin lattice in Fotin et al. Nature 2004, albeit our structure contains the vesicle) occurs primarily at the level of V~1~H regulatory subunit, a part of vATPase suggested to regulate the vATPase activity by numerous reports.

In order to obtain additional experimental evidence for the model, we have performed cryo-electron tomography on purified CCVs, and on purified CCVs that were partially uncoated (vATPase is not well visible in the tightly packed clathrin-coated vesicles) with a help of Dr Ruben Fernandez-Busnadiego at the MPI for Biochemistry, Munich, Germany. We have detected signals reminiscent of clathrin "filaments" in the close proximity of the signals reminiscent of vATPases, and the measured dimensions were in agreement with our model (see Video 1 and [Author response image 2](#respfig2){ref-type="fig"}), but more work is needed here to ensure that the observed signals correspond to clathrin and vATPase. Thus, we prefer not to report on the cryo-electron tomography data at this stage.

We have now added additional data and information in the revised manuscript, and would like to stress that we consider that the clathrin coat, and not clathrin or adaptor proteins alone, block the vATPase activity. We have prepared an animation using original structures and following numerous cited literature, and we have stated at several instances that this is just a hypothetical model, and that more experimental work is needed to understand how clathrin coat inhibits the vATPase activity while the vesicles are coated.

> 4\) There are some problems with the immunoblots.
>
> 4a) First, there is no information anywhere about what antibodies were used. This is essential information because there is so much variability in the quality of individual antibodies. Was the same anti-clathrin heavy chain antibody used throughout? In Figure 1C, lots of non-specific bands seem to be appearing, while in Supplementary Figure 8, it gives the sort of strong and specific signal one would expect, especially in purified CCVs.

We have now included a table that lists all antibodies and their sources (see new Table 2). In the original manuscript, several different antibodies against clathrin LC and HC were used. We have repeated all experiments with anti-clathrin HC and LC antibodies obtained from Abcam and Millipore, respectively (see new Figure 1C).

> 4b) The dot blots (Figure 4B and Figure 1---figure supplement 1) are not acceptable. The dots are of varying sizes and appearances, and the method assumes that all of the antibodies are entirely monospecific, when clearly some of them are not. They need to be replaced by Western blots.

Figure 1---figure supplement 1: Please note that the dot blots were used just to optimize the CCV purification protocol. Specifically, we have monitored the distribution of clathrin and VAMP2, an integral synaptic vesicle protein, in the D~2~O/sucrose gradient by dot blot, since there was not enough material to run the classical Western blot. We have chosen anti- VAMP2 (SySy) and anti-clathrin LC (Millipore) antibodies, which are affinity-purified antibodies with proven specificity (numerous publications and manufacturers' web pages, we have verified the specificity of these antibodies ourselves as well). If the reviewers still consider these data not acceptable, we will remove them. However, we consider that it is useful to show a key protocol optimization step in more details.

Figure 4B: It was reported that incubation with the Tris-buffer removes clathrin coat proteins (Maycox et al., 1992), and similar "stripping" approaches were often used to extract coat proteins (e.g., clathrin, adaptor proteins, auxilin) from coated vesicles for further purification. We have verified this also in our experiments, and dot blots were replaced by Western blots (see new Figure 4E).

> 4c) There are some inconsistencies in the Western blots. In particular, in the blot in Figure 3A, where equal amounts of protein were loaded into the SV and CCV lanes, there is a stronger signal for VAMP2 and other SV proteins in the SV lane than in the CCV lane, which is understandable because much of the protein in the CCV lane is clathrin and other coat proteins. Similarly, in Supplementary Figure 8, there is a stronger signal for VAMP2 in the SV lane. However, there is also a stronger signal for α-adaptin (AP-2) in the SV lane, which doesn\'t make sense. Moreover, the iBAQ values, which are reasonably quantitative within a single sample, clearly indicate that this is not the case. If one normalizes the iBAQ data to assume that there is twice as much VAMP2 in the SVs as in the CCVs (which is the sort of difference suggested by the Western blot), then there should be about four times as much α-adaptin in the CCVs as in the SVs, not less α-adaptin in the CCVs.

We thank the reviewers for this comment. We have quantified the protein concentration in both SV and CCV samples, and have loaded the same amount of protein to be able to compare two samples. As correctly pointed out by the reviewers, much of the protein in the CCV sample is contributed by clathrins and other coat proteins, hence a difference in the overall level of integral SV proteins (e.g. VAMP2). We have repeated Western blots for α-adaptin, with the similar vexing result as originally reported. At present, we cannot explain this discrepancy (maybe it is a problem of the antibody). Given that this minor point is not relevant for the key message of the manuscript, we have removed the α-adaptin Western blot data from the revised version.

> 5\) The authors say: \"Clathrin-mediated endocytosis is a classic example of vesicle formation mediated by a coat assembly, and it is the prominent endocytic pathway at the synapse.\" This sentence should be toned down as CME is not necessarily the sole endocytosis pathway for synaptic vesicle endocytosis (Watanabe et al. 2013; Kononenko et al. 2014). Moreover, it is very relevant to this study to know where clathrin is used. If it is on the plasma membrane, then acidification will take place in the CCV or, as proposed here, after uncoating. However, if clathrin is required on endosome-like vesicles (Watanabe et al., 2014) then acidification could occur before clathrin coated bud formation, making the issue of acidification less relevant.

We agree and have toned down the quoted sentence.

> 6\) The difference in CCVs vs. SVs is revealed by assays performed in a buffer composed of 300 mM glycine, 4 mM MgSO4, 10 mM MOPS, pH 7.4, devoid of \"membrane permeable ions\". How is the pH equilibrated to 7.4? In this buffer, SVs can acidify only to pH 7.0, far from the physiological pH. In the \"full characterization\" of SVs, Figure 2---figure supplement 2, by adding 30 mM chloride SVs can acidify to pH 5.5, the physiological pH. Why did the authors use the buffer without membrane permeable ions? They should repeat the measures with chloride to assess whether CCVs are able to acidify or not in this more physiological context.

We have used a buffer without membrane permeable ions (as originally reported in Farsi et al., Science 2016) to exclude the contribution of any ion/proton exchanger to the difference that was observed between SV and CCV samples. That said, we have repeated these experiments in the presence of chloride now. Note that a significant difference between SV and CCV samples is present also under these conditions (new Figure 2---figure supplement 3).

Regarding the question about luminal pH of vesicles being equilibrated to 7.4, we have shown in our previous work (Farsi et al., 2016) that we did not observe any difference between ratiometric values of pHluorin-probe in purified vesicles before and after addition of FCCP (a proton ionophore) at pH 7.4, while acidifying the lumen by incubation of vesicles at pH 5.5 in the presence of FCCP significantly decreased the ratiometric value. This indicates that vesicles equilibrate with their surrounding buffer during purification and subsequent immobilization on glass coverslips.

> 7\) Is there any evidence that acidification is delayed at synaptic terminals? Available data on acidification, based on spH measurements in cultured neurons, seems to be at odds with a significant delay (Atluri and Ryan 2006; Leitz and Kavalali 2011; Soykan et al., 2017). This should be discussed. Moreover, there are mutant mice (synaptojanin KO, endophilin TKO) for which CCV uncoating seems to be delayed. Is there any indication that acidification is delayed in these mice?

Quenching of the pH-sensitive fluorescent protein pHluorin reflects the combined rate of endocytosis and re-acidification of SV proteins tagged with pHluorin (e.g., Miesenböck et al., 1998; Granseth et al., 2006; Atluri and Ryan 2006; Balaji and Ryan, 2007; Balaji et al., 2008; Leitz and Kavalali 2011). Studies with pHluorin-based probes are useful, but not straight-forward since these probes are affected both by endocytic and/or acidification processes, and such processes are stimulation-, model- and temperature-dependent. By using synaptopHluorin, Atluri and Ryan (2006) have suggested that SVs re-acidify within approximately 4-5s. By using vGLUT-pHluorin, Leitz and Kavalali (2011) found that majority of endocytic events happen within 4s after stimulation. Using the rapid application of quenching solutions to separate endocytosis from acidification, Soykan et al. (2017) have also detected two endocytic phases, rapid and slow, at 37°C. In addition, Balaji et al. (2008) tried to separate the components of endocytosis and acidification: they found that the endocytic time constant (measured by the vGLUT-pHluorin probe) was \~6s at 36°C, and \~14s at 25°C, while vesicle acidification took \~4s.

Recent morphological studies based on optogenetic stimulation followed by rapid freezing proposed the existence of "ultrafast endocytosis" that can recover synaptic vesicle membrane with 30-300 ms after stimulation through the formation of synaptic endosomes (Watanabe et al., 2013a, 2013b, 2014). These synaptic endosomes could be further resolved by clathrin-mediated endocytic process into coated vesicles as fast as \~3s after stimulation (Watanabe et al., 2014).

Our finding that clathrin coat blocks vesicle acidification until the coat is removed corroborates several of aforementioned studies, and it contributes to the better understanding of these processes. Yet, as apparent from this short overview, the kinetics of vesicle recycling at the synapses is still intensely studied, and the contributions of temperature and stimulation strength are presently being examined. In addition, the nature of intermediates that occur after stimulation is not well understood. This is a complex topic that requires a detailed technical context to be adequately addressed, however, if is considered absolutely necessary, we will include it.

The delayed post-stimulus recovery observed through pHluorin quenching in auxilin (Yim et al., 2010), synaptojanin-1 KO (Mani et al., Neuron 2007) and endophilin-A TKO (Milosevic et al., Neuron 2011) mutants suggests a delayed kinetics of endocytic process, a delay in the acidification of the newly formed vesicles, or both (note that both mutants accumulate CCVs and endosome-like structures). Notably, based on our data (Milosevic et al. Neuron 2011) as well as Mani et al. (2007) and Yim et al. (2010), the loss of endophilin, synaptojanin-1 or auxilin does not cause a block in uncoating, but a kinetic delay. Similarly, neurotransmission is impaired, but not abolished, and functional vesicles can eventually be regenerated from coated structures (Milosevic et al., 2011). This point is now mentioned in the manuscript.

[^1]: These authors contributed equally to this work.
